Santenna Chenchula MS, PhD

Dr. Santenna Chenchula MS, PhD

Clinical Pharmacology, All India Institute of Medical Sciences Bhopal, Bhopal, India
orcid
Clinical Pharmacologyst

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Santenna Chenchula MS, PhDSantenna Chenchula MS, PhD
Santenna Chenchula MS, PhD
KVKota Vidyasagar
Kota Vidyasagar
SPSaman Pathan
Saman Pathan
SSSushil Sharma
Sushil Sharma
MCMadhav Rao Chavan
Madhav Rao Chavan
SMSofia Mudda
Sofia Mudda
A COVID-19 patient often presents with multiple comorbidities and is associated with adverse outcomes. A comprehensive assessment of the prevalence of comorbidities in patients with COVID-19 is essential. This study aimed to assess the prevalence of comorbidities, severity and mortality with regard to geographic region, age, gender and smoking status in patients with COVID-19. A systematic review and multistage meta-analyses were reported using PRISMA guidelines. PubMed/MEDLINE, SCOPUS, Google Scholar and EMBASE were searched from January 2020 to October 2022. Cross-sectional studies, cohort studies, case series studies, and case–control studies on comorbidities reporting among the COVID-19 populations that were published in English were included. The pooled prevalence of various medical conditions in COVID-19 patients was calculated based on regional population size weights. Stratified analyses were performed to understand the variations in the medical conditions based on age, gender, and geographic region. A total of 190 studies comprising 105 million COVID-19 patients were included. Statistical analyses were performed using STATA software, version 16 MP (StataCorp, College Station, TX). Meta-analysis of proportion was performed to obtain pooled values of the prevalence of medical comorbidities: hypertension (39%, 95% CI 36–42, n = 170 studies), obesity (27%, 95% CI 25–30%, n = 169 studies), diabetes (27%, 95% CI 25–30%, n = 175), and asthma (8%, 95% CI 7–9%, n = 112). Moreover, the prevalence of hospitalization was 35% (95% CI 29–41%, n = 61), intensive care admissions 17% (95% CI 14–21, n = 106), and mortality 18% (95% CI 16–21%, n = 145). The prevalence of hypertension was highest in Europe at 44% (95% CI 39–47%, n = 68), obesity and diabetes at 30% (95% CI, 26–34, n = 79) and 27% (95%CI, 24–30, n = 80) in North America, and asthma in Europe at 9% (95% CI 8–11, n = 41). Obesity was high among the ≥ 50 years (30%, n = 112) age group, diabetes among Men (26%, n = 124) and observational studies reported higher mortality than case–control studies (19% vs. 14%). Random effects meta-regression found a significant association between age and diabetes (p < 0.001), hypertension (p < 0.001), asthma (p < 0.05), ICU admission (p < 0.05) and mortality (p < 0.001). Overall, a higher global prevalence of hypertension (39%) and a lower prevalence of asthma (8%), and 18% of mortality were found in patients with COVID-19. Hence, geographical regions with respective chronic medical comorbidities should accelerate regular booster dose vaccination, preferably to those patients with chronic comorbidities, to prevent and lower the severity and mortality of COVID-19 disease with novel SARS-CoV-2 variants of concern (VOC).

1 August 2019 in Journal of Experimental Pharmacology
Verified
Journal Article
Open access
PDF file
Santenna Chenchula MS, PhDSantenna Chenchula MS, PhD
Santenna Chenchula MS, PhD
SKSunil Kumar
Sunil Kumar
SBS Balakrishnan
S Balakrishnan
RJRatinder Jhaj
Ratinder Jhaj
SAShah Newaz Ahmed
Shah Newaz Ahmed
Purpose: Pain is an unpleasant sensation, but a protective mechanism of our body. It is the most common medical complaint requiring a visit to a physician. The new non-steroidal anti-inflammatory drug (NSAID) – zaltoprofen, is a preferential COX-2 inhibitor. It also inhibits bradykinin-induced nociceptive responses by blocking the B2 receptor-mediated pathway in the primary sensory neurons. The present study was conducted to evaluate and compare the anti-nociceptive activity of zaltoprofen with a conventional NSAID – piroxicam, in a mouse model of acute pain using hot plate and tail flick tests. Materials and methods: Twenty-four adult Swiss albino mice (20–25 g) of either sex were used in this study. Oral zaltoprofen and piroxicam were used as test and standard drugs respectively. Anti-nociceptive activity was evaluated and compared using hot plate and tail flick tests. Results: In comparison to the control group (vehicle), zaltoprofen showed a significant increase in reaction time at various time periods in the hot plate and tail flick tests. In the hot plate method, zaltoprofen groups (15 and 20 mg/kg) showed a significant elevation in pain threshold in comparison to control group (vehicle) (p<0.001). In the tail flick model also, zaltoprofen groups (15 and 20 mg/kg) showed a significant increase in the reaction time in comparison to control group (vehicle). In both the analgesiometer assays, zaltoprofen was found to be non-inferior compared to a standard drug – piroxicam (positive control). Conclusion: Our study concludes that zaltoprofen is an effective analgesic agent in various pain models. Our results support that zaltoprofen has therapeutic potential for treating pain disorders and is non-inferior to a standard drug – piroxicam.

11 March 2024 in Heliyon
Verified
Journal Article
Open access
KAKuttiappan Anitha
Kuttiappan Anitha
Santenna Chenchula MS, PhDSantenna Chenchula MS, PhD
Santenna Chenchula MS, PhD
VSVijayaraj Surendran
Vijayaraj Surendran
BSBhatt Shvetank
Bhatt Shvetank
PRParameswar Ravula
Parameswar Ravula
PRPadmavathi R
Padmavathi R
Nanotheranostics, especially those employing biomimetic approaches, are of substantial interest for molecular imaging and cancer therapy. The incorporation of diagnostics and therapeutics, known as cancer theranostics, represents a promising strategy in modern oncology. Biomimetics, inspired by nature, offers a multidisciplinary avenue with potential in advancing cancer theranostics. This review comprehensively analyses recent progress in biomimetics-based cancer theranostics, emphasizing its role in overcoming current treatment challenges, with a focus on breast, prostate, and skin cancers. Biomimetic approaches have been explored to address multidrug resistance (MDR), emphasizing their role in immunotherapy and photothermal therapy. The specific areas covered include biomimetic drug delivery systems bypassing MDR mechanisms, biomimetic platforms for immune checkpoint blockade, immune cell modulation, and photothermal tumor ablation. Pretargeting techniques enhancing radiotherapeutic agent uptake are discussed, along with a comprehensive review of clinical trials of global nanotheranostics. This review delves into biomimetic materials, nanotechnology, and bioinspired strategies for cancer imaging, diagnosis, and targeted drug delivery. These include imaging probes, contrast agents, and biosensors for enhanced specificity and sensitivity. Biomimetic strategies for targeted drug delivery involve the design of nanoparticles, liposomes, and hydrogels for site-specific delivery and improved therapeutic efficacy. Overall, this current review provides valuable information for investigators, clinicians, and biomedical engineers, offering insights into the latest biomimetics applications in cancer theranostics. Leveraging biomimetics aims to revolutionize cancer diagnosis, treatment, and patient outcomes.

5 August 2024 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
AKAnitha K
Anitha K
MSMandeep Kumar Singh
Mandeep Kumar Singh
KKKomal Kohat
Komal Kohat
STSri Varshini T
Sri Varshini T
Santenna Chenchula MS, PhDSantenna Chenchula MS, PhD
Santenna Chenchula MS, PhD
SBShvetank Bhatt
Shvetank Bhatt

25 December 2023 in Clinica Chimica Acta
Verified
Journal Article
Closed access
KAKuttiappan Anitha
Kuttiappan Anitha
BPBhargavi Posinasetty
Bhargavi Posinasetty
KKK. Naveen Kumari
K. Naveen Kumari
Santenna Chenchula MS, PhDSantenna Chenchula MS, PhD
Santenna Chenchula MS, PhD
RPR. Padmavathi
R. Padmavathi
CRChikatipalli Radhika
Chikatipalli Radhika

10 September 2024 in Journal of Affective Disorders
Verified
Journal Article
Closed access
Santenna Chenchula MS, PhDSantenna Chenchula MS, PhD
Santenna Chenchula MS, PhD
ASAtal Shubham
Atal Shubham
JRJhaj Ratinder
Jhaj Ratinder
RARozatkar Abhijit
Rozatkar Abhijit
MTModak Tamonud
Modak Tamonud
SBS. Balakrishnan
S. Balakrishnan